Driven by Purpose

The history of our success is evident in our ability to apply it in the future. We are pioneering science in the field of virus-specific T cell (VST) therapies. Our innovative spirit lives beyond the lab.

Our Leadership

David Hallal
Chief Executive Officer
David Hallal is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies.
Vikas Sinha
President and Chief Financial Officer
Vikas Sinha is AlloVir's President and Chief Financial Officer and brings over 25 years of experience in executive finance roles within the biopharmaceutical industry.
Ann Leen, PhD
Chief Scientific Officer
For more than 20 years, Dr. Ann Leen has led innovative discovery and translational research focused on developing novel T cell-based therapies.
Agustin Melian, MD
Chief Medical Officer & Head of Global Medical Sciences
Prior to joining AlloVir, Dr. Augustin Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals.
Jeroen van Beek, PhD
Chief Commercial Officer
Jeroen van Beek is responsible for commercial strategy, planning and operations at AlloVir. Before joining AlloVir, Dr. van Beek was the Chief Commercial Officer and Senior Vice-President at Tricida.
Ercem Atillasoy, M.D.
Chief Regulatory and Safety Officer
Dr. Atillasoy, Chief Regulatory and Safety Officer, has nearly 25 years of experience leading drug, biologic, and infectious disease product development.
Edward Miller
General Counsel
Edward Miller has more than 25 years of diverse legal and business experience in the biotechnology and pharmaceutical industry and related fields.
Dana Alexander, MBA
Senior Vice President, Technical Operations
Mr. Alexander brings more than 20 years of experience in biopharmaceutical operations for start-up, late clinical-stage, and commercial biologic products.

Life @ AlloVir

Mission-driven teams developing transformative cell therapies for patients deserve transformative benefits. We make sure your life outside the lab is as purposeful as your life inside it.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
PTO Policies
Making sure that you have the freedom to time off when you need to is an important part of our culture. Life beyond the lab includes a flexible approach to PTO; you take it when you need it.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
401k Plans
We offer 401(k) matching, employer-paid life short and long-term disability, and life insurance.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
Healthcare
Our health plans include medical, vision, and dental covered at 90%, as well as Flexible Spending Accounts (FSA) and Dependent Care Accounts (DCA).
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
Family Leave
Growing and taking care of your family is as important as the work you do. We offer a generous parental leave program that allows you to do just that.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
Cell phone and commuter reimbursement
Being connected and getting where you need to go is an important part of your work. We offer cell phone and commuter reimbursement programs that acknowledge the time you spend in and out of the office.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now

Advisors

Elizabeth Stoner, MD, MS
Senior Clinical Advisor
A distinguished biopharma executive, Liz is an MPM Executive Partner who brings decades of international industry experience to her role guiding and growing MPM’s and its affiliated portfolio companies.
Cliona Rooney, PhD
SAB Member, Professor of Pediatrics, Baylor College of Medicine
Dr. Rooney is a Professor in the Departments of Pediatrics, Molecular Virology and Microbiology, and Immunology and Director of Translational Research Laboratories at the Center for Cell and Gene Therapy at Baylor College of Medicine.
Mitchell H. Finer, PhD
Senior Scientific Advisor
Dr. Finer has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine for the last three decades.
Helen Heslop, MD, DSC
SAB Member, Director of Baylor College of Medicine’s Center for Cell and Gene Therapy
Dr. Heslop is Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital.
Malcolm Brenner, MD, PhD
Member of SAB, Board of Directors, Founding Director of Baylor College of Medicine’s Center for Cell and Gene Therapy
Dr. Brenner is the founding director of the Center for Cell and Gene Therapy and the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics

Board of Directors

Jeffrey Bornstein
Managing Partner at Generation Capital Partners and Founder and Principal of Whipstick Ventures LLC
Diana M. Brainard, MD
Senior Vice President and Head of the Virology Therapeutic Area at Gilead Sciences, Inc.
John Wilson
CEO, Wilson Wolf Manufacturing Corporation
Ansbert Gadicke, MD
Co-founder and Managing Director, MPM Ventures
Morana Jovan-Embiricos, PhD
Managing Partner, F2 Ventures
Malcolm Brenner, MD, PhD
Member of SAB, Board of Directors, Founding Director of Baylor College of Medicine’s Center for Cell and Gene Therapy
Juan F. Vera, MD
Associate Professor, Baylor College of Medicine
Vikas Sinha
President and Chief Financial Officer
David Hallal
Chief Executive Officer

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?